Presentation is loading. Please wait.

Presentation is loading. Please wait.

AEs, SAEs, and EAEs – An Overview MTN 020 Training.

Similar presentations


Presentation on theme: "AEs, SAEs, and EAEs – An Overview MTN 020 Training."— Presentation transcript:

1 AEs, SAEs, and EAEs – An Overview MTN 020 Training

2 Layers of Safety  Study participants  Study site staff team  Clinical affairs staff at SCHARP  MTN-020 Protocol Safety Review Team (PSRT)  NIAID Vaccine and Prevention Data and Safety Monitoring Board (DSMB) site

3 Any untoward medical occurrence in a clinical research participant administered an investigational product that does not necessarily have a causal relationship with the investigational product. An AE can therefore be an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product. ICH E6, Glossary 1.2 Definition: Adverse Event

4 Any medical condition, problem, sign, symptom, or finding identified as ongoing in a study participant at the time of enrollment (prior to randomization). Pre-existing conditions are not AEs. However, if a pre-existing condition worsens in severity and/or frequency after randomization, the worsened condition is an AE. Definition: Pre-Existing Condition

5 Case 1  A participant reports that she has hypertension during her baseline medical history  Has an AE occurred? No Yes Not enough information to determine

6 Case 2  A participant reports a migraine headache occurring two weeks before her Month 4 visit.  Has an AE occurred? No Yes Not enough information to determine

7 Case 3  A participant has a positive pregnancy test result at her Month 7 visit.  Has an AE occurred? Yes No Not enough information

8 Case 4  A participant reports new vulvar erythema at her Month 10 visit. You note erythema on pelvic exam that covers approximately 30% of her vulva.  Is this an AE? Yes No Not enough information  What if the vulvar erythema had not been seen on exam – does this change your answer?

9 An AE that meets study protocol criteria for reporting on adverse event case report forms For MTN 020, this means reportable on an Adverse Experience (AE) Log CRF AEs that do not meet the protocol criteria for reporting on adverse event forms will be recorded on the Grade 1 AE Log CRF (GAE Log) Definition: Reportable Adverse Event

10 Reportable Adverse Events There are six types of AEs that are reportable in MTN 020. Can you name them?

11 Reportable AEs  All genital, genitourinary, and reproductive system AEs except Fetal losses  All AEs of severity Grade 2 or higher  All serious AEs  All AEs that results in permanent discontinuation of study product use  All lab test abnormalities  AEs that meet expedited reporting requirement  Any AE not covered above will go on a Grade 1 AE Log form

12 AE Log or Grade 1 AE Log CRF?  Grade 1 vaginal itching  Grade 3 headache  Grade 1 nausea  Grade 1 urinary tract infection  Grade 1 weakness prompting hospital admission to rule out stroke  Grade 1 allergic reaction to the vaginal ring

13 Pelvic Exam Finding AEs  Report any and all new abnormal findings as AEs Specify anatomical location (e.g., vulvar, vaginal, cervical) Use finding term as it appears in FGGT or Pelvic Exam CRF, whichever is more specific For example, do not report “genital sore.” Instead, report “vaginal ulcer.” Describing AEs

14 Genital Bleeding AEs  Report only bleeding that is different from baseline May be expected (due to menses or contraceptive use) or unexpected Use appropriate term from FGGT/SSP Use separate terms for pregnancy-related bleeding – SSP Section 10.6  If bleeding associated with pelvic exam finding, report finding as the AE The bleeding is a sign of the finding, - comment on in Comments field Describing AEs

15 Bleeding during pregnancy prior to the onset of labor (regardless of trimester) will be graded per the table below: Antepartum Bleeding

16  The severity of all AEs must be graded as Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Potentially Life-Threatening Grade 5 = Death  Assign grades based on the DAIDS Female Genital Grading Table (FGGT) and DAIDS Table for Grading Adult and Pediatric Adverse Events (Toxicity Table)  See SSP Section 11.3 for tips and guidance AE Severity

17 Severity Grading of Vaginal Candidiasis  Normal = absence of symptoms regardless of candida test results  Grade 1 = positive wet mount or other laboratory test for yeast, with mild symptoms  Grade 2 = positive wet mount or other laboratory test for yeast, with moderate to severe symptoms  Grade 3: Not applicable  Grade 4: Not applicable

18  The relationship of each AE to study product must be assessed as: Related Not Related Relationship to Study Product

19  Pre-clinical and clinical profile of the study products: protocol, package inserts, investigators brochures, other published information  Timing of product use relative to onset, resolution, and/or recurrence of the AE  Likelihood of observing the AE in the study population in the absence of product use  Presence of other conditions or exposures that could have caused the AE  Clinical judgment, including judgment of biologic plausibility Factors to Consider

20  All AEs – reportable and not reportable – must be followed clinically until the AE resolves or stabilizes  Resolution = return to baseline severity grade  Stabilization = persistence at a severity grade above baseline for 3 consecutive monthly evaluations AE Outcome

21  At each visit, an authorized study clinician should review all previously reported ongoing AEs to evaluate their current status  Oftentimes the outcome of an AE will not be available when the AE is first documented  In such cases, documentation should be updated when the final outcome becomes available AE Outcome

22  If an AE increases in severity or frequency, the higher grade AE must be documented (and reported) as a new AE  If an AE completely resolves and then recurs at a later date, the second occurrence must be documented (and reported) as a new AE AE Outcome

23 Any untoward medical occurrence that at any dose:  Results in death  Is life-threatening  Requires inpatient hospitalization or prolongation of existing hospitalization  Results in persistent or significant disability/ incapacity  Is a congenital anomaly/birth defect Definition: Serious Adverse Event Important medical events that may not be immediately life- threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of the above-listed outcomes, also may be considered serious.

24  Seriousness ≠ severity  SAEs are a subset of all AEs  All SAEs are reportable on AE Log forms  All AEs must be assessed by authorized study staff to determine whether they meet the definition of serious  source document and record on AE Log form Seriousness of Adverse Events

25 AE that meets criteria in the study protocol for additional reporting for rapid review and assessment by DAIDS Reporting period begins once the participant is randomized and continues through the final study visit (Study Exit/Termination Visit) Only suspected, unexpected serious adverse reactions (SUSARs) as defined in Version 2.0 of the EAE Manual will be reported to DAIDS NEED TO CHECK ABOVE Expedited Adverse Event

26 Let’s Discuss More Adverse Events Suppose a participant has a grade 3 decreased hemoglobin at her semi- annual visit Is this an adverse event? 1. Yes 2. No 3. Not enough information to determine

27 Let’s Discuss More Adverse Events Suppose a participant has a grade 4 decreased hemoglobin at her semi- annual visit Is this serious? 1. Yes 2. No 3. Not enough information to determine

28 Let’s Discuss Adverse Events Suppose a participant has an argument with her partner related to her participation in the study. She was late meeting him because a study visit took longer than expected. He thinks the study is taking up too much of her time and he does not want to hear any more from her about safe sex and using condoms. The argument escalates and he pushes her to the floor, resulting in a laceration on her forehead and a broken collarbone. She is treated in the emergency department and then admitted to the hospital for observation related to her head injury. How many AEs have occurred? 1. One 2. Two 3. None

29 Let’s Discuss Adverse Events Suppose a participant has an argument with her partner related to her participation in the study. She was late meeting him because a study visit took longer than expected. He thinks the study is taking up too much of her time and he does not want to hear any more from her about safe sex and using condoms. The argument escalates and he pushes her to the floor, resulting in a laceration on her forehead and a broken collarbone. She is treated in the emergency department and then admitted to the hospital for observation related to her head injury. How many AEs are EAEs? 1. One 2. Two 3. None

30 Let’s Discuss Adverse Events Suppose a participant has a positive pregnancy test at her Month 6 visit. At her Month 7 visit, her pregnancy test is negative. She reports having no symptoms between visits and is surprised that she is no longer pregnant. Is this an adverse event? 1. Yes 2. No 3. Not enough information to determine

31 A Few Extra Reporting Tips  Only symptomatic BV confirmed by wet mount should be reported as an AE  Only report symptomatic candida infections confirmed by wet mount should be reported as an AE  Chlamydia should be “genitourinary chlamydia infection”  Gonorrhea should be “genitourinary gonorrhea infection”  Suspected herpes lesions should be captured as “ulcers”

32 Questions?


Download ppt "AEs, SAEs, and EAEs – An Overview MTN 020 Training."

Similar presentations


Ads by Google